These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 2170998

  • 1. Effects of U50,488H on locomotor activity in the hamster.
    Schnur P, Walker JM.
    Pharmacol Biochem Behav; 1990 Aug; 36(4):813-6. PubMed ID: 2170998
    [Abstract] [Full Text] [Related]

  • 2. The kappa-opioid receptor agonist, U50,488H, exerts antidystonic activity in a mutant hamster model of generalized dystonia.
    Richter A, Löscher W.
    Eur J Pharmacol; 1993 May 19; 236(2):289-94. PubMed ID: 8391460
    [Abstract] [Full Text] [Related]

  • 3. Behavioural effect of pretreatment with opioid antagonists and sigma binding site ligands on the abnormal motor response produced by the kappa opioid agonist U50,488H in guinea pigs.
    Brent PJ.
    Neuropharmacology; 1993 Aug 19; 32(8):751-60. PubMed ID: 8413839
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effects of the kappa opiate U50,488 in the substantia nigra pars reticulata.
    Thompson LA, Walker JM.
    Brain Res; 1990 May 28; 517(1-2):81-7. PubMed ID: 2165438
    [Abstract] [Full Text] [Related]

  • 5. The kappa-opioid receptor agonist U50,488H induces acute physical dependence in guinea-pigs.
    Brent PJ, Chahl LA, Cantarell PA, Kavanagh C.
    Eur J Pharmacol; 1993 Sep 14; 241(2-3):149-56. PubMed ID: 7902288
    [Abstract] [Full Text] [Related]

  • 6. Ventral pallidal microinjections of receptor-selective opioid agonists produce differential effects on circling and locomotor activity in rats.
    Hoffman DC, West TE, Wise RA.
    Brain Res; 1991 Jun 07; 550(2):205-12. PubMed ID: 1653084
    [Abstract] [Full Text] [Related]

  • 7. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
    Zhu J, Luo LY, Li JG, Chen C, Liu-Chen LY.
    J Pharmacol Exp Ther; 1997 Aug 07; 282(2):676-84. PubMed ID: 9262330
    [Abstract] [Full Text] [Related]

  • 8. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ, Doty P, Negus SS, Mattox SR, Dykstra LA.
    J Pharmacol Exp Ther; 1990 Jul 07; 254(1):13-22. PubMed ID: 2164087
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the interaction of mu and kappa opioid agonists on locomotor behavior in the horse.
    Mama KR, Pascoe PJ, Steffey EP.
    Can J Vet Res; 1993 Apr 07; 57(2):106-9. PubMed ID: 8490803
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of T cell superantigen responses following treatment with the kappa-opioid agonist U50,488H.
    Guan L, Eisenstein TK, Adler MW, Rogers TJ.
    J Neuroimmunol; 1997 May 07; 75(1-2):163-8. PubMed ID: 9143250
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of primary murine macrophage cytokine production in vitro following treatment with the kappa-opioid agonist U50,488H.
    Alicea C, Belkowski S, Eisenstein TK, Adler MW, Rogers TJ.
    J Neuroimmunol; 1996 Jan 07; 64(1):83-90. PubMed ID: 8598393
    [Abstract] [Full Text] [Related]

  • 12. A kappa opiate agonist, U50,488H, enhances energy expenditure in rats.
    Mandenoff A, Seyrig JA, Betoulle D, Brigant L, Melchior JC, Apfelbaum M.
    Pharmacol Biochem Behav; 1991 May 07; 39(1):215-7. PubMed ID: 1656474
    [Abstract] [Full Text] [Related]

  • 13. Rotational behavior mediated by dopaminergic and nondopaminergic mechanisms after intranigral microinjection of specific mu, delta and kappa opioid agonists.
    Matsumoto RR, Brinsfield KH, Patrick RL, Walker JM.
    J Pharmacol Exp Ther; 1988 Jul 07; 246(1):196-203. PubMed ID: 2839661
    [Abstract] [Full Text] [Related]

  • 14. kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor.
    Taylor CC, Wu D, Soong Y, Yee JS, Szeto HH.
    J Pharmacol Exp Ther; 1996 May 07; 277(2):877-84. PubMed ID: 8627570
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of interleukin-1 and tumor necrosis factor-alpha synthesis following treatment of macrophages with the kappa opioid agonist U50, 488H.
    Belkowski SM, Alicea C, Eisenstein TK, Adler MW, Rogers TJ.
    J Pharmacol Exp Ther; 1995 Jun 07; 273(3):1491-6. PubMed ID: 7791124
    [Abstract] [Full Text] [Related]

  • 16. Kappa agonists inhibit gastric emptying but not acid secretion in rhesus monkeys.
    Touzeau PL, Shea-Donohue T.
    J Pharmacol Exp Ther; 1990 Jun 07; 253(3):1010-6. PubMed ID: 1972746
    [Abstract] [Full Text] [Related]

  • 17. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice.
    Kuzmin AV, Semenova S, Gerrits MA, Zvartau EE, Van Ree JM.
    Eur J Pharmacol; 1997 Mar 05; 321(3):265-71. PubMed ID: 9085036
    [Abstract] [Full Text] [Related]

  • 18. Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation.
    Li JG, Zhang F, Jin XL, Liu-Chen LY.
    J Pharmacol Exp Ther; 2003 May 05; 305(2):531-40. PubMed ID: 12606694
    [Abstract] [Full Text] [Related]

  • 19. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
    Millan MJ, Morris BJ, Herz A.
    J Pharmacol Exp Ther; 1988 Nov 05; 247(2):721-8. PubMed ID: 2846827
    [Abstract] [Full Text] [Related]

  • 20. Opiate agonists activate feeding in Limax: comparison of in vivo and in vitro effects.
    Wong M, Delaney K, Gelperin A.
    Behav Neurosci; 1991 Feb 05; 105(1):15-24. PubMed ID: 1851015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.